Rahul Banerjee, MD, FACP

home / authors / rahul-banerjee-md

Articles

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD

March 3rd 2025

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple Myeloma

Ehsan Malek, MD ;Peter Leif Bergsagel, MD;Rahul Banerjee, MD, FACP;Krina Patel, MD, MSc ;Tiffany Richards, PhD, ANP-BC, AOCNP ;Rafael Fonseca, MD;Sridevi Rajeeve, MD ;C. Ola Landgren, MD, PhD

November 25th 2024

Panelists discuss how the use of CAR T-cell therapy in earlier lines of treatment for relapsed/refractory multiple myeloma could potentially improve long-term outcomes, considering factors such as patient selection, optimal timing, and the impact on subsequent treatment options.

Bispecific Selection in BCMA-failed Therapy for Relapsed Refractory Multiple Myeloma

Ehsan Malek, MD ;Peter Leif Bergsagel, MD;Rahul Banerjee, MD, FACP;Krina Patel, MD, MSc ;Tiffany Richards, PhD, ANP-BC, AOCNP ;Rafael Fonseca, MD;Sridevi Rajeeve, MD ;C. Ola Landgren, MD, PhD

November 18th 2024

Panelists discuss how to select appropriate bispecific antibody therapies for patients with relapsed/refractory multiple myeloma who have failed BCMA-targeted treatments, considering factors such as alternative targets, mechanisms of resistance, and emerging clinical data to provide effective subsequent treatment options.

Sequencing Therapies for Relapsed Refractory Multiple Myeloma: Bispecifics or CAR T-cell Therapy

Ehsan Malek, MD ;Peter Leif Bergsagel, MD;Rahul Banerjee, MD, FACP;Krina Patel, MD, MSc ;Tiffany Richards, PhD, ANP-BC, AOCNP ;Rafael Fonseca, MD;Sridevi Rajeeve, MD ;C. Ola Landgren, MD, PhD

November 18th 2024

Panelists discuss how to optimize the sequencing of bispecific antibodies and CAR T-cell therapies in relapsed/refractory multiple myeloma, considering factors such as patient characteristics, disease burden, and the unique advantages of each approach to maximize treatment efficacy and patient outcomes.

Patient Case: A 67-Year-Old, BCMA-Naïve, Woman with Relapsed Refractory Multiple Myeloma

Ehsan Malek, MD ;Peter Leif Bergsagel, MD;Rahul Banerjee, MD, FACP;Krina Patel, MD, MSc ;Tiffany Richards, PhD, ANP-BC, AOCNP ;Rafael Fonseca, MD;Sridevi Rajeeve, MD ;C. Ola Landgren, MD, PhD

November 11th 2024

Panelists discuss how to tailor treatment strategies for a 67-year-old, BCMA-naïve woman with relapsed/refractory multiple myeloma, weighing the potential benefits of BCMA-targeted therapies against other available options in the context of her specific clinical presentation.

Patient Case: A 68-Year-Old Woman with Triple Class Exposed Relapsed Refractory Multiple Myeloma

Ehsan Malek, MD ;Peter Leif Bergsagel, MD;Rahul Banerjee, MD, FACP;Krina Patel, MD, MSc ;Tiffany Richards, PhD, ANP-BC, AOCNP ;Rafael Fonseca, MD;Sridevi Rajeeve, MD ;C. Ola Landgren, MD, PhD

November 11th 2024

Panelists discuss how to approach treatment decisions for a 68-year-old woman with triple-class exposed relapsed/refractory multiple myeloma, considering factors such as prior therapies, disease characteristics, and emerging treatment options to optimize her care.

CARTITUDE-4: Cilta-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma

Ehsan Malek, MD ;Peter Leif Bergsagel, MD;Rahul Banerjee, MD, FACP;Krina Patel, MD, MSc ;Tiffany Richards, PhD, ANP-BC, AOCNP ;Rafael Fonseca, MD;Sridevi Rajeeve, MD ;C. Ola Landgren, MD, PhD

November 4th 2024

Panelists discuss how the CARTITUDE-4 trial results show cilta-cel's superior efficacy over standard of care therapies in treating relapsed/refractory multiple myeloma, potentially reshaping treatment paradigms for this patient population.

KarMMa-3: Ide-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma

Ehsan Malek, MD ;Peter Leif Bergsagel, MD;Rahul Banerjee, MD, FACP;Krina Patel, MD, MSc ;Tiffany Richards, PhD, ANP-BC, AOCNP ;Rafael Fonseca, MD;Sridevi Rajeeve, MD ;C. Ola Landgren, MD, PhD

November 4th 2024

Panelists discuss how the KarMMa-3 trial results demonstrate superior efficacy of ide-cel compared to standard of care therapies in patients with relapsed/refractory multiple myeloma, potentially establishing a new benchmark for treatment in this setting.

Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma

Ehsan Malek, MD ;Peter Leif Bergsagel, MD;Rahul Banerjee, MD, FACP;Krina Patel, MD, MSc ;Tiffany Richards, PhD, ANP-BC, AOCNP ;Rafael Fonseca, MD;Sridevi Rajeeve, MD ;C. Ola Landgren, MD, PhD

October 28th 2024

Panelists discuss how ide-cel, a CAR T-cell therapy, demonstrates promising real-world outcomes in patients with relapsed/refractory multiple myeloma, potentially offering a valuable treatment option for this challenging patient population.

Treatment Strategies in Relapsed Refractory Multiple Myeloma

Ehsan Malek, MD ;Peter Leif Bergsagel, MD;Rahul Banerjee, MD, FACP;Krina Patel, MD, MSc ;Tiffany Richards, PhD, ANP-BC, AOCNP ;Rafael Fonseca, MD;Sridevi Rajeeve, MD ;C. Ola Landgren, MD, PhD

October 28th 2024

Panelists discuss how novel therapeutic approaches and combination regimens are reshaping the landscape of treatment for patients with relapsed/refractory multiple myeloma, offering new hope for improved outcomes and quality of life.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD

September 2nd 2024

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

A panel of 4 experts on multiple myeloma

Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

June 7th 2024

The panel concludes its discussion with key takeaways on the evolving role of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Insights from CARTITUDE-4 and KarMMa-3 in R/R MM

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 31st 2024

Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.

CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 31st 2024

Myeloma specialists have a comprehensive discussion on CAR T-cell therapy, highlighting treatment selection considerations, adverse event management strategies, unmet needs, and ongoing research.

Key Takeaways from the CARTITUDE-1 and KarMMa Studies

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 24th 2024

Focusing on later lines of therapy for patients with relapsed/refractory multiple myeloma, the panel provides key takeaways on the CARTITUDE-1 and KarMMa trials that investigated cilta-cel and ide-cel.

How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 24th 2024

Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.

The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 17th 2024

Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.

The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 17th 2024

A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy, highlighting BCMA as a target and treatment administration practices.

CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

October 10th 2023

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.

Olverembatinib in Ponatinib-Resistant CML: Considerations for Later-Line Therapy

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

October 3rd 2023

Expert insight into the later-line efficacy and tolerability of olverembatinib, a third generation TKI, in ponatinib-resistant, refractory chronic myeloid leukemia populations.

Debate on Efficacy and Patient Selection With Ixa-Pom-Dex in Relapsed/Refractory MM

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

October 3rd 2023

Leading experts discuss the potential benefits and challenges of using ixazomib pomalidomide-dexamethasone as a treatment option for relapsed myeloma patients, considering factors like efficacy, overall survival, and patient demographics.

Cross Q&A: Evaluating Ponatinib and Asciminib as 3L Therapy in CML

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

October 3rd 2023

Considerations for selecting between ponatinib and asciminib as third-line therapies for CML based on factors such as disease burden, mutations, and patient tolerability.

Ixa-Pom-Dex as Second-Line Therapy in Relapsed/Refractory MM: Alliance A061202

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

October 3rd 2023

Rahul Banerjee, MD, FACP, discusses the Alliance A061202 trial, presenting the potential benefits and red flags of using ixazomib-pomalidomide-dexamethasone combination in relapsed myeloma treatment.

Asciminib in CML Treatment: Efficacy and Responses Shown in the ASCEMBL Study

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

September 26th 2023

A review of promising results from the ASCEMBL study, highlighting asciminib's superior efficacy, well-tolerated profile, and potential impact on chronic myeloid leukemia treatment options.

Cross Q&A: Exploring the Role of Ixazomib in Relapsed/Refractory Multiple Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

September 26th 2023

Key insights on real-world applications of the REMIX study, which evaluated real-world effectiveness and tolerability of the ixazomib-based regimen in relapsed/refractory multiple myeloma.

Cross Q&A: Managing Cardiovascular Risks in CML Treatment

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

September 26th 2023

A panel of experts discusses the challenges and considerations surrounding cardiovascular risks associated with ponatinib treatment for chronic myeloid leukemia, emphasizing the need for multidisciplinary collaboration and individualized treatment strategies.

REMIX Study: Ixa-Len-Dex for Relapsed/Refractory Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

September 26th 2023

Outcomes of the REMIX study investigating the effectiveness and tolerability of ixa-len-dex in real-world relapsed/refractory myeloma patients, exploring progression-free survival, overall response rate, and safety.

Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

September 19th 2023

Expert insights into tailoring treatment for biochemical relapse in multiple myeloma patients, considering disease progression and the impact of various therapy lines on treatment decisions.

Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

September 19th 2023

An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.

Cross Q&A: Dosing Ponatinib in CML to Balance Efficacy and Cardiovascular Safety

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

September 19th 2023

Experts discuss dosing strategies and risk factors for arterial occlusive events in ponatinib treatment for chronic myeloid leukemia, emphasizing the importance of balancing disease control and patient safety.

1 2 >